CompareMarketResearchRequest a sample
Home / Healthcare / New Approach Methodologies Nonclinical Testing

Healthcare · Market report

New Approach Methodologies Nonclinical Testing Market Size, Share and Forecast 2026-2036

The global new approach methodologies nonclinical testing market is worth USD 2.2 bn in 2026 and is forecast to reach USD 7.4 bn by 2036, growing at a 13.0% CAGR. United States is the largest country market and In vitro cell-based and 3D models is the largest by technology segment.

USD 2.2 bnMarket size 2026
USD 7.4 bnForecast 2036
13.0%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global new approach methodologies nonclinical testing market is worth USD 2.2 bn in 2026 and is forecast to reach USD 7.4 bn by 2036, growing at a 13.0% CAGR. United States is the largest country market and In vitro cell-based and 3D models is the largest by technology segment.

ScopeFee-based testing services built on human-relevant methods that replace or reduce animal studies: cell-based assays, organoids, organ-on-chip, computational toxicology and omics screening for drug, chemical and cosmetic safety.
IndustryHealthcare
Value 2025USD 1.9 bn
Value 2026USD 2.2 bn
Value 2036USD 7.4 bn
CAGR 2026-203613.0%
Volume 202642,471 studies
Volume 2036118,269 studies
Average price 2026USD 51,000 per studie
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

New Approach Methodologies Nonclinical Testing market size and forecast, 2026-2036

Exhibit 1The global new approach methodologies nonclinical testing market is forecast to grow from USD 2.2 bn in 2026 to USD 7.4 bn by 2036, more than triplingGlobal market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 13.0%
New Approach Methodologies Nonclinical Testing market value, 2025 to 2036Market value by year. 2025: USD 1.9 bn; 2026: USD 2.2 bn; 2027: USD 2.4 bn; 2028: USD 2.8 bn; 2029: USD 3.1 bn; 2030: USD 3.5 bn; 2031: USD 4.0 bn; 2032: USD 4.5 bn; 2033: USD 5.1 bn; 2034: USD 5.8 bn; 2035: USD 6.5 bn; 2036: USD 7.4 bn. Compound annual growth rate 2026 to 2036: 13.0%.20252.2 bn20264.0 bn20317.4 bn203613.0% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 2.2 bn
2027USD 2.4 bn
2028USD 2.8 bn
2029USD 3.1 bn
2030USD 3.5 bn
2031USD 4.0 bn
2032USD 4.5 bn
2033USD 5.1 bn
2034USD 5.8 bn
2035USD 6.5 bn
2036USD 7.4 bn

New Approach Methodologies Nonclinical Testing market segmentation

By technology

Exhibit 2In vitro cell-based and 3D models is the largest segment by technology, with 36.0% of 2026 revenueEstimated share of 2026 global revenue, by technology
New Approach Methodologies Nonclinical Testing market share by technology, 2026Share of 2026 revenue by technology. In vitro cell-based and 3D models: 36.0%; In silico and computational toxicology: 22.0%; High-throughput and omics screening: 20.0%; Organ-on-chip and microphysiological systems: 12.0%; Other methods: 10.0%.In vitro cell-based and 3D models36.0%In silico and computational toxicology22.0%High-throughput and omics screening20.0%Organ-on-chip and microphysiological systems12.0%Other methods10.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
In vitro cell-based and 3D models36.0%28.7%USD 780 mn10.5%
Organ-on-chip and microphysiological systems12.0%26.5%USD 260 mn22.3%
In silico and computational toxicology22.0%22.8%USD 477 mn13.4%
High-throughput and omics screening20.0%15.9%USD 433 mn10.5%
Other methods10.0%6.1%USD 217 mn7.5%

By application

Exhibit 3Toxicity and safety assessment adds the most revenue by application, growing from USD 996 mn in 2026 to USD 3.2 bn by 2036Estimated revenue in USD by application, 2026 and 2036 forecast
New Approach Methodologies Nonclinical Testing market by application, 2026 and 2036Revenue by application in 2026 and 2036. Toxicity and safety assessment: USD 996 mn in 2026, USD 3.2 bn in 2036, change +220%; Efficacy and disease models: USD 433 mn in 2026, USD 1.8 bn in 2036, change +317%; ADME and pharmacokinetics: USD 477 mn in 2026, USD 1.7 bn in 2036, change +250%; Other: USD 260 mn in 2026, USD 694 mn in 2036, change +167%.20262036 forecastChangeToxicity and safety assessment+220%996 mn3.2 bnEfficacy and disease models+317%433 mn1.8 bnADME and pharmacokinetics+250%477 mn1.7 bnOther+167%260 mn694 mn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Toxicity and safety assessment46.0%43.3%USD 996 mn12.3%
ADME and pharmacokinetics22.0%22.7%USD 477 mn13.3%
Efficacy and disease models20.0%24.5%USD 433 mn15.3%
Other12.0%9.4%USD 260 mn10.3%

By end user

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Pharmaceutical and biotechnology55.0%55.9%USD 1.2 bn13.2%
Contract research organisations25.0%27.7%USD 542 mn14.2%
Chemical and cosmetics12.0%10.2%USD 260 mn11.2%
Academic and regulatory8.0%6.2%USD 173 mn10.2%

By model system

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
In vitro cell models40.0%38.0%USD 866 mn12.4%
Organs-on-chips16.0%21.0%USD 347 mn16.1%
In silico models24.0%25.0%USD 520 mn13.5%
Organoids and 3D models20.0%16.0%USD 433 mn10.5%

By phase of use

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Discovery stage42.0%40.0%USD 910 mn12.4%
Preclinical safety36.0%36.0%USD 780 mn13.0%
Regulatory submission support22.0%24.0%USD 477 mn14.0%

Top 25 countries for new approach methodologies nonclinical testing by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 84.5% of 2026 revenue and the 25 countries below together hold 95.7%.

Exhibit 4United States is the largest country market at USD 823 mn in 2026, and the three largest countries hold 54.0% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
New Approach Methodologies Nonclinical Testing market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 823 mn, 38.0%; Germany: USD 173 mn, 8.0%; United Kingdom: USD 173 mn, 8.0%; China: USD 152 mn, 7.0%; France: USD 108 mn, 5.0%; Switzerland: USD 108 mn, 5.0%; Japan: USD 108 mn, 5.0%; Netherlands: USD 65 mn, 3.0%; Canada: USD 65 mn, 3.0%; South Korea: USD 54 mn, 2.5%.United States823 mn 38.0%Germany173 mn 8.0%United Kingdom173 mn 8.0%China152 mn 7.0%France108 mn 5.0%Switzerland108 mn 5.0%Japan108 mn 5.0%Netherlands65 mn 3.0%Canada65 mn 3.0%South Korea54 mn 2.5%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 823 mn38.0%USD 2.8 bn12.8%
2GermanyUSD 173 mn8.0%USD 529 mn11.8%
3United KingdomUSD 173 mn8.0%USD 581 mn12.9%
4ChinaUSD 152 mn7.0%USD 721 mn16.9%
5FranceUSD 108 mn5.0%USD 331 mn11.8%
6SwitzerlandUSD 108 mn5.0%USD 331 mn11.8%
7JapanUSD 108 mn5.0%USD 331 mn11.8%
8NetherlandsUSD 65 mn3.0%USD 221 mn13.0%
9CanadaUSD 65 mn3.0%USD 221 mn13.0%
10South KoreaUSD 54 mn2.5%USD 213 mn14.7%
11AustraliaUSD 36 mn1.7%USD 121 mn12.9%
12BelgiumUSD 30 mn1.4%USD 101 mn12.8%
13DenmarkUSD 26 mn1.2%USD 88 mn12.9%
14SwedenUSD 23 mn1.1%USD 76 mn12.9%
15IrelandUSD 20 mn0.9%USD 67 mn12.9%
16AustriaUSD 19 mn0.9%USD 62 mn12.9%
17IsraelUSD 17 mn0.8%USD 57 mn12.8%
18SingaporeUSD 14 mn0.6%USD 46 mn12.8%
19SpainUSD 11 mn0.5%USD 38 mn12.8%
20ItalyUSD 11 mn0.5%USD 36 mn13.0%
21IndiaUSD 9.8 mn0.5%USD 32 mn12.8%
22TaiwanUSD 8.4 mn0.4%USD 28 mn12.7%
23NorwayUSD 6.7 mn0.3%USD 23 mn13.0%
24PolandUSD 5.6 mn0.3%USD 19 mn13.0%
25TurkeyUSD 5.0 mn0.2%USD 16 mn12.5%
Rest of worldUSD 94 mn4.3%USD 307 mn12.6%
Exhibit 5United States and China account for 48% of the USD 5.2 bn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
New Approach Methodologies Nonclinical Testing market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 2.2 bn. United States: +USD 1.9 bn; China: +USD 569 mn; United Kingdom: +USD 408 mn; Germany: +USD 356 mn; France: +USD 223 mn; 20 other countries: +USD 1.5 bn; Rest of world: +USD 213 mn. Market value 2036: USD 7.4 bn.Market value 20262.2 bnUnited States+1.9 bnChina+569 mnUnited Kingdom+408 mnGermany+356 mnFrance+223 mn20 other countries+1.5 bnRest of world+213 mnMarket value 20367.4 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • Charles River Laboratories
  • Labcorp
  • Eurofins Scientific
  • WuXi AppTec

Group 2: Regional and specialist players

  • Evotec
  • Certara
  • Inotiv
  • MatTek
  • Ncardia
  • Pharmaron
  • XCellR8
  • Axion BioSystems

Group 3: Emerging and niche players

  • Emulate
  • MIMETAS
  • CN Bio
  • InSphero
  • Simulations Plus
  • TissUse
  • Hesperos
  • AxoSim
  • Vivodyne
  • Curi Bio

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the new approach methodologies nonclinical testing market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 13.0% is calculated from the resulting values.

The market is divided by technology, by application, by end user, by model system, by phase of use. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the new approach methodologies nonclinical testing market?

The global new approach methodologies nonclinical testing market is estimated at USD 1.9 bn in 2025 and USD 2.2 bn in 2026.

How fast will the new approach methodologies nonclinical testing market grow?

It is forecast to reach USD 7.4 bn by 2036, a compound annual growth rate of 13.0% from 2026, an increase of USD 5.2 bn.

Which country is the largest market for new approach methodologies nonclinical testing?

United States is the largest market by revenue at USD 823 mn in 2026, 38.0% of the global total. The three largest countries together hold 54.0%.

Which country is growing fastest?

Among the ten largest markets, China is growing fastest at 16.9% a year from 2026 to 2036.

Which new approach methodologies nonclinical testing segment is largest?

In the by technology split, In vitro cell-based and 3D models is the largest segment with 36.0% of 2026 revenue.

Who are the leading new approach methodologies nonclinical testing companies?

Global leaders include Charles River Laboratories, Labcorp, Eurofins Scientific, WuXi AppTec.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Healthcare

← Neurosurgery & Spine Robots Next Generation Sequencing →

All Healthcare markets →

Request a sample